1 / 69

Sample_Global Pharmacovigilance Market - Growth, Trends and Forecasts 2018 - 2029

Pharmacovigilance Market, By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, and Phase IV), By Service Provider (In-house, Contract, and Outsourcing), By Type of Reporting (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining), By End User (Hospitals, Pharmaceutical Companies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034<br>

ankita73
Télécharger la présentation

Sample_Global Pharmacovigilance Market - Growth, Trends and Forecasts 2018 - 2029

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL PHARMACOVIGILANCE MARKET (2018-2030) 1 Report

  2. 2 • USE THIS REPORTTO: • Develop an understanding of the current market dynamics and growthopportunities • Understand an in-depth analysis and market forecast for the pharmacovigilance market • Analyze the competitive landscape, including key strategies and recent developments of the top vendors in the pharmacovigilancemarket • Get an understanding of recent developments in the pharmacovigilancemarket REPORTID: Domain:Healthcare Sub-domain:Pharmaceuticals Base Year:2017 Historical Period:2012-2020 Forecast Period: 2021-2030 Industry Reports | Consulting | Intelligence Center + 1 860 531 2701| sales@prophecymarketinsights.com| www.prophecymarketinsights.com Report

  3. TABLE OFCONTENTS 3 1.INTRODUCTION 6. MARKETDYNAMICS 1.1 MarketDefinition 6.1Drivers 1.2 Scope of theStudy 6.1.1 Increasing Drug Consumption and DrugDevelopment 1.3 StudyDeliverables 6.1.2 Increasing Incidences of ADR and DrugToxicity 1.4 StudyAssumptions 6.1.3 Growing Trend of Outsourcing PharmacovigilanceServices 2. RESEARCHMETHODOLOGY 6.2Restraints 3. EXECUTIVESUMMARY • High Risk Associated with DataSecurity • Lack of GlobalRegulatory Harmonization Standardization for Adverse Event DataCollection 4. KEYINFERENCES andData 5. MARKETOVERVIEW 5.1 Current MarketScenario 6.3Opportunities 5.2 Industry Attractiveness – Porter’s Five ForcesAnalysis 6.3.1 Increasing Focus on PersonalizedMedicine 5.2.1 Bargaining Power ofSuppliers 6.4Challenges 5.2.2 Bargaining Power ofConsumers 6.4.1 Undeveloped Healthcare Infrastructure and Complexityin 5.2.3 Threat of NewEntrants DataStorage • Threat of Substitute Products andServices • Degree ofCompetition Report

  4. TABLE OFCONTENTS 4 • MARKET SEGMENTATION ANDANALYSIS • By Clinical TrialPhase • Preclinical • PhaseI • PhaseII • PhaseIII • PhaseIV • By Service Provider • In-house • ContractOutsourcing • By Type of Reporting • SpontaneousReporting • Intensified ADRReporting • Targeted SpontaneousReporting • Cohort EventMonitoring • EHR Mining • By End User • Hospitals • PharmaceuticalCompanies • Others • By Geography • NorthAmerica • UnitedStates • Canada • Mexico • Europe • UnitedKingdom • Germany • France • Italy • Spain • Rest ofEurope • Asia-Pacific • India • China • Japan • Australia • SouthKorea • Rest ofAsia-pacific Report

  5. TABLE OFCONTENTS 5 • Overview • Products andStrategies SWOT • RecentDevelopments • IBM Corporation • Overview • Products andStrategies SWOT • RecentDevelopments • ArisGlobal • Overview • RecentDevelopments • Foresight Group InternationalAG • Overview • RecentDevelopments • ICON PLC • Overview • Products andStrategies SWOT • RecentDevelopments • SouthAmerica • Brazil • Argentina • Rest of SouthAmerica • Middle East &Africa • GCC • SouthAfrica • Rest ofMEA • COMPETITIVE LANDSCAPE & COMPETITIVELANDSCAPE • Accenture • Overview • Products andStrategies SWOT • Recent Developments • Cognizant • Overview • Products andStrategies SWOT • Recent Developments • Laboratory Corporation of AmericaHoldings Report

  6. TABLE OFCONTENTS 6 • Capgemini • Overview • Products andStrategies SWOT • RecentDevelopments • United BioSource Corporation Overview • Products andStrategies SWOT • RecentDevelopments • WiproLtd • Overview • Products andStrategies SWOT • RecentDevelopments • BioClinica • Overview • RecentDevelopments • ITClinical • Overview • RecentDevelopments 9. FUTURE OF THEMARKET Report

  7. 1.INTRODUCTION 7 Report

  8. INTRODUCTION MARKETDEFINITION 8 • This report studies the global pharmacovigilance market. It includes a detailed analysis of spontaneous reporting, cohort event monitoring, and EHRmining. • Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug- related problems. The focus of pharmacovigilance is on ADR (adverse drug reactions) and drug toxicity. The global pharmacovigilance market comprises all types of adverse event reporting conducted during clinical trials in hospitals, pharmacies, and other healthcaresectors. • The market has been segmented by clinical trial phase, service provider, type of reporting, and end user. By clinical trial phase, the market is segmented further, into Preclinical, Phase I, Phase II, Phase III, And PhaseIV. • The market, on the basis of service providers, is segmented into in-house and contract outsourcing. By type of reporting, the market is segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHRmining. • By end user, the market is segmented into pharmaceutical companies, academic research organization, andothers. • A holistic study of the market has been carried out, by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific microeconomic influences that were needed to analyze the future trends of the market. The research uncovers many paradigm shifts regarding regional competitive advantage and dynamics in the market studied, primarily on theservices Report

  9. INTRODUCTION SCOPE OF THESTUDY 9 Preclinical PhaseI By Clinical TrialPhase PhaseII PhaseIII PhaseIV In-house By ServiceProvider ContractOutsourcing SpontaneousReporting Intensified ADRReporting GLOBAL PHARMACOVIGILANCE MARKET Targeted SpontaneousReporting By Type of Reporting Cohort EventMonitoring EHRMining Hospitals By EndUser PharmaceuticalCompanies Others NorthAmerica Europe Asia-Pacific By Geography (with country-wiseanalysis) Latin America Middle East &Africa Report

  10. INTRODUCTION STUDYASSUMPTIONS 10 • Global- and regional-level analysis, along with forecast, for the marketstudied. • Study of the effects of exogenous and endogenous factors, namely, demographic, economic, and political factors, among others, which may affect the global market. • Porter’s five forces framework, incorporating the factors influencing each force, to determine the intensity ofcompetition. • Segment- and sub-segment-level analysis of the market, for the review and forecastperiods. • Identification of key factors instrumental in changing the market scenario, exploiting new opportunities, and gaining a competitiveedge. • Analysis of key players, a detailed study of their current strategic interests, and key financial performanceindicators. • The market number provided for 2017 is based on the financials reported in the proxy statements of the major players tracked in thismarket. Report

  11. INTRODUCTION STUDYDELIVERABLES 11 AIM AND OBJECTIVE OF THESTUDY Global- and regional-level analysis, and forecast, of the pharmacovigilancemarket. STUDYPERIOD BASEYEAR FORECASTPERIOD 2017 2018-2030 2015-2023 SEGMENTSCOVERED GEOGRAPHICALSCOPE MARKETDYNAMICS INDUSTRYANALYSIS SEGMENTANALYSIS KEYVENDORS COMPETITIVELANDSCAPE Report

  12. 2. RESEARCHMETHODOLOGY 12 Report

  13. INTRODUCTION 13 • The research process adopted for this study is a highly structured, two-stage process: size estimation of the review period and the market engineering for the forecast period, of the global-, country-, and segment-level data, which leads to the data generation process (DGP) for the studiedvariables. • The size estimations are carried out through multiple bottom-up and top-down approaches. The bottom-up approach includes, the examining of historical revenues of key players, studying the size of the applications, value and supply chain analysis, and end-user demand, which are then cross-validated against secondary and primaryresources. • The top-down approach is an astute research process, where the global market sizing is carried out through the secondary research, validated then by primary industryexperts. • Source: Prophecy Market Insights • In this report, to analyze future trends, for the studied market during the forecast period, we have incorporated rigorous statistical and econometric methods, which are further scrutinized by secondary and primary sources and by our in-house experts, supported by our extensive data intelligencerepository. • The market is studied holistically, from both the demand- and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns during the review period, which affect price, demand, and consumption trends. As the study demands analyzing long-term trends in the market, the identification of factors influencing the market is based on the fundamentality of the market studied. Through secondary and primary researches, endogenous and exogenous factors are identified, and are transformed to quantitative data through data extraction, which are then used for inferentialpurposes. Report

  14. RESEARCHMETHODOLOGY RESEARCHPHASES 14 • StatisticalReports • ResearchJournals • GovernmentPublications • News Articles and PressReleases • External Subject-matterExperts • SelectOfficials • In-house Subject-matterExperts • Doctors • Sales Managers/ ProductManagers • Medicalprofessionals • Insights from Data and Forecasts areCompiled DISCUSSION GUIDE PRIMARY RESEARCH ECONOMETRIC MODELLING EXPERT VALIDATION DATA TRIANGULATION REPORT WRITING SECONDARY RESEARCH • Company-related Queries • Market-relatedQueries • CompanyFinancials • Revalidation of Numbers throughPrimaries • Combination of Top-down and Bottom-up Approaches • ForecastingModel PrimaryInterviews Primary Interviews - Along the ValueChain CEOs/CFOs 6% 6% BoardMembers 31% ResearchHeads 45% Manufacturers 20% Strategic DecisionMakers 55% EndUsers FinancialAdvisors 11% 26% Investors Report

  15. 3. EXECUTIVESUMMARY 15 Report

  16. EXECUTIVESUMMARY 16 KeyFindings Global PharmacovigilanceMarket 9000 Pharmacovigilance Market: Revenue in USD million, Global,2015-2023 • The global pharmacovigilance market (henceforth referred to as the market studied) is expected to witness a CAGR of 13.2%, over the forecast period. xx 8000 7000 6000 Revenue (in USDmillion) 5000 4,342.0 3,835.4 4000 3,388.7 2,994.2 3000 2000 1000 0 2015 2016 2017 2018 2023 Year Report

  17. 4. KEYINFERENCES 17 Report

  18. KEYINFERENCES 18 • Due to the increasing number of investigative new drug (IND) applications being filed, the demand for pharmacovigilance is expected to grow at a steady pace. • The government initiatives in emerging economies, aimed at the promotion of drug discovery and healthcare advancement, are also expected to propel the growth of themarket. • The strategic partnership among pharmaceutical companies and CROs is expected to have a significant impact on the growth of the market. North America and Europe are the hubs of primary research on drugdiscovery. • North America contributes the highest share in the global market. This is attributed to the concentration of drug manufacturing companies in this region. As companies invest heavily on drug development, the usage of pharmacovigilance services is high in the UnitedStates. • Increasing drug consumption and drug development, the increasing incidences of adverse drug reactions (ADR) and drug toxicity, and the increasing trend of outsourcing pharmacovigilance services are the major factors contributing to the growth of the pharmacovigilance market in the forecastperiod. • However, high risk associated with data security and lack of global regulatory harmonization and data standardization for adverse event data collection are the major factors that restrict the growth of themarket. Report

  19. 5. MARKETOVERVIEW 19 5.1 Current MarketScenario 5.2 Porter's Five ForcesAnalysis Report

  20. CURRENT MARKETSCENARIO 20 The market is currently growing also due to the increasing incidences of adverse drugreaction The growth of the global pharmacovigilance market is due to the growing trend of outsourcing pharmacovigilance services. The cost of these services is significantly lower in developing regions, as compared to developedregions. (ADR). It is estimated that ADR is one of the leading causes of deaths, after heart disease, cancer, and stroke, globally. With the increase in the number of cases of ADR, there has been a significant burden on the healthcaresystem. The need to reduce the burden of ADR has led to an increase in the demand for pharmacovigilance services. The lack of global regulatory harmonization and data standardization for adverse event data collection and high risk associated with data security are hindering the growth of themarket studied. Accenture, Clinquest Group BV, Cognizant, IBM Corporation, Capgemini, and BioClinica are some of the major players in the market studied. Report

  21. PORTER’S FIVEFORCES ANALYSIS MARKETINSIGHTS 21 • The Porter’s five forces model studies the five identified competitive forces that shape every industry and market, in order to determine the intensity of the competition, and thus, the profitability and attractiveness of the industry. The objective of the growth strategy is to adapt to these competitive forces in a manner that may improve the position of the organization. This study includes an exhaustive Porter’s five forces framework, incorporating the factors influencing each force, to analyze the market from a microeconomic perspective. THREAT OF NEWENTRANTS BENIGNAND THREAT OF SUBSTITUTES LOW GROWING COMPETITIVE RIVARLY HIGH • In the study, Porter’s five forces are analyzed considering the factors influencing each force and quantifying the factors through primaries and quantitative analysis. The quantified factors are further mapped out to derive the impact of each force on competitivedynamics. MODERATE BARGAINING POWER OF SUPPLIERS MODERATE& EVOLVING BARGAINING POWER OF BUYERS Report

  22. PORTER’S FIVEFORCES ANALYSIS MARKETINSIGHTS 22 THREAT OF NEWENTRANTS • There is a high level of capital investment involved in setting up pharmacovigilance services, and it needs the involvement and coordination of IT and CSV teams to support the system, in order to meet business requirements and grant infrastructure availability and performancestandards. Governmentpolicy 10 9 8 7 6 5 4 3 2 1 0 Industry profitability (Market CAGR) Capitalrequirements • There are various government regulatory requirements that are need to be met for pharmacovigilance services to function. Access todistribution Economies ofscale • Threat of new entrants isLow. Economies of product differences Switching costs or sunkcosts Productdifferentiation Report

  23. PORTER’S FIVEFORCES ANALYSIS MARKETINSIGHTS 23 BARGAINING POWER OF BUYERS Buyer concentration to firm concentrationratio 10 9 8 7 6 5 4 3 2 1 0 Differential advantage (uniqueness) ofindustry products Degree of dependencyupon existing channels of distribution Bargaining leverage, particularly inindustries with high fixedcosts Buyer pricesensitivity Buyer switching costs relative to firmswitching costs Availability of existing substituteproducts Buyerinformation availability Force downprices Report

  24. 27 6.1Drivers 6.2Restraints 6. MARKETDYNAMICS 6.3Opportunities 6.4Challenges Report

  25. DRIVERS, RESTRAINTS & OPPORTUNITIES MARKETDYNAMICS 28 INCREASING DRUG CONSUMPTION ANDDRUG DEVELOPMENT High INCREASING INCIDENCES OF ADR AND DRUGTOXICITY MarketDrivers GROWING TREND OF OUTSOURCING PHARMACOVIGILANCE SERVICES Impact Low Low Impact MarketRestraints LACK OF GLOBALREGULATORY HARMONIZATION AND DATA STANDARDIZATION FORADVERSE EVENT DATACOLLECTION HIGH RISK ASSOCIATEDWITH DATASECURITY High Report

  26. DRIVERS MARKETDYNAMICS 29 INCREASING DRUG CONSUMPTION AND DRUGDEVELOPMENT • Increasing incidences of lifestyle diseases, such as diabetes, hypertension, and cardiac disorders, as a result of sedentary lifestyle, lack of physical activities, changing lifestyle patterns, and poor diet lead to the increased consumption of drugs, which, in turn, augments the demand for drug monitoring and further fuels the growth of the marketstudied. • As of 2012, 117 million people were suffering from chronic disorders, such as heart disease, stroke, cancer, Type 2 diabetes, obesity, and arthritis, which increased the consumption ofdrugs. • With growing drug consumption, the need for regular monitoring of drugs has also increased, thereby boosting the market studied. Owing to changing climate, infectious diseases are also on the rise. Increasing urbanization also causes a surge in drug consumption and drug development, developing the need to have themregulated. • The drug development process is subjected to a strict regulatory regime that is evolving continuously, and therefore causes major focus on pharmacovigilance services. The major factor driving the pharmacovigilance market is the growth of drug development processes as a result of the increasing number of health disorders. • The large number of pipeline drugs also contribute substantial growth to the pharmacovigilance market, as they help understand the adverse actions and side- effects of drugs. There were 7,493 drugs in pre-clinical phase in the year 2017, and this is projected to reach 8,040 in 2018. These statistics indicate increasing focus on pharmacovigilanceservices. Report

  27. MARKETSEGMENTATION 36 • By Clinical TrialPhase • By ServiceProvider 7.SEGMENTATION 7.3 By Type of Reporting • By EndUser • ByGeography Report

  28. BY CLINICAL TRIALPHASE MARKETSEGMENTATION 37 • Preclinical • PhaseI 7.1 SEGMENTATION – BY CLINICAL TRIAL PHASE 7.1.3 PhaseII • PhaseIII • PhaseIV Report

  29. BY CLINICAL TRIALPHASE MARKETSEGMENTATION 38 PharmacovigilanceMarket: Revenue Share (%), by Clinical Trial, Global,2017 0.5% Pharmacovigilance Market : Revenue in USD million, by Clinical Trial, Global,2015-2023 3.5% 6.0% 20.0% 70.2% Preclinical PhaseI PhaseII PhaseIII PhaseIV Report

  30. MARKET SEGMENTATION PRECLINICAL CLINICAL TRIALPHASE 39 Fig.3 Pharmacovigilance Market: Revenue in USD million, Preclinical, Global,2015-2023 35 xx 30 25 Revenue (in USDmillion) xx 20 18.2 16.5 15.0 15 10 5 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  31. MARKET SEGMENTATION CLINICAL TRIALPHASE PHASEI 40 . Fig.4 Pharmacovigilance Market: Revenue in USD million, Phase I, Global,2015-2023 500 450 400 350 Revenue (in USDmillion) 300 xx 250 xx xx 200 179.6 150 100 50 0 2015 2016 2017 2018 2023 Year Report

  32. MARKET SEGMENTATION PHASEII CLINICAL TRIALPHASE 41 Fig.5 Pharmacovigilance Market: Revenue in USD million, Phase II, Global,2015-2023 300 250 200 Revenue (in USDmillion) xx 150 xx xx 104.8 100 50 0 2015 2016 2017 2018 2023 Source: Prophecy Market Insights Year Report

  33. MARKET SEGMENTATION PHASEIII CLINICAL TRIALPHASE 42 Fig.6 Pharmacovigilance Market: Revenue in USD million, Phase III, Global,2015-2023 1800 xx 1600 1400 1200 Revenue (in USDmillion) 1000 xx xx 800 676.9 598.8 600 400 200 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  34. MARKET SEGMENTATION CLINICAL TRIALPHASE PHASEIV 43 Fig.7 Pharmacovigilance Market: Revenue in USD million, Phase IV, Global,2015-2023 • This phase is also considered as the late phase or post-marketing surveillance. Phase IV studies are done to collect information on the drug's effect on various populations, in terms of any side effects associated with its long-term use. 6000 xx 5000 4000 Revenue (in USDmillion) xx 3000 2690.6 2374.6 2095.9 2000 1000 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  35. MARKETSEGMENTATION BY SERVICEPROVIDER 44 7.2.1In-house 7.2 SEGMENTATION – BY SERVICEPROVIDER 7.2.2 ContractOutsourcing Report

  36. MARKETSEGMENTATION BY SERVICEPROVIDER 45 Fig.9 Pharmacovigilance Market : Revenue Share (%), by Service Provider, Global,2017 Fig.8 Pharmacovigilance Market : Revenue in USD billion, by Service Provider, Global,2015-2023 36.3% 63.8% In-house ContractOutsourcing Report

  37. MARKET SEGMENTATION BY SERVICEPROVIDER IN-HOUSE 46 Fig.10 Pharmacovigilance Market: Revenue in USD million, In-house, Global,2015-2023 2500 xx 2000 Revenue (in USDmillion) xx 1500 1390.3 1291.9 1197.7 1000 500 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  38. MARKET SEGMENTATION CONTRACT OUTSOURCING BY SERVICEPROVIDER 47 . Fig.11 Pharmacovigilance Market: Revenue in USD million,Contract Outsourcing, Global,2015-2023 7000 xx 6000 5000 Revenue (in USDmillion) 4000 xx 3000 xx 2096.8 1796.5 2000 1000 0 2015 2016 2017 2018 2023 Year Report

  39. BY TYPE OFREPORTING MARKETSEGMENTATION 48 • SpontaneousReporting • Intensified ADRReporting 7.3 SEGMENTATION – BY TYPE OFREPORTING 7.3.3 Targeted SpontaneousReporting • Cohort Event Monitoring • EHR Mining Report

  40. BY TYPE OFREPORTING MARKETSEGMENTATION 49 Fig.13 Pharmacovigilance Market: Revenue Share (%), by Type of Reporting, Global,2017 Fig.12 Pharmacovigilance Market : Revenue in USD billion, by Type of Reporting, Global,2015-2023 xx xx xx xx xx Spontaneous Reporting Targeted Spontaneous Reporting EHRMining Intensified ADRReporting Cohort EventMonitoring Report

  41. SPONTANEOUSREPORTING MARKETSEGMENTATION BY TYPE OFREPORTING 50 Fig.14 Pharmacovigilance Market: Revenue in USD million, Spontaneous Reporting, Global,2015-2023 4000 xx 3500 3000 Revenue (in USDmillion) 2500 xx 2000 1732.7 1527.9 1500 1347.4 1000 500 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  42. INTENSIFIED ADRREPORTING MARKETSEGMENTATION BY TYPE OFREPORTING 51 Fig.15 Pharmacovigilance Market: Revenue in USD million, Intensified ADR Reporting, Global, 2015-2023 1000 900 xx 800 700 Revenue (in USDmillion) 600 xx 500 419.0 371.5 400 329.4 300 200 100 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  43. BY TYPE OFREPORTING TARGETED SPONTANEOUS REPORTING MARKETSEGMENTATION 52 Fig.16 Pharmacovigilance Market: Revenue in USD million, Targeted Spontaneous Reporting , Global,2015-2023 600 xx 500 400 Revenue (in USDmillion) xx 300 x 235.9 209.6 200 100 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  44. COHORT EVENTMONITORING MARKETSEGMENTATION BY TYPE OFREPORTING 53 Fig.17 Pharmacovigilance Market: Revenue in USD million, Cohort Event Monitoring, Global,2015-2023 2000 xx 1800 1600 1400 Revenue (in USDmillion) 1200 xx 1000 xx xx 800 688.7 600 400 200 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  45. EHRMINING MARKETSEGMENTATION BY TYPE OFREPORTING 54 Fig.1 Pharmacovigilance Market: Revenue in USD million, by Type of Reporting, EHR mining, Global,2015-2023 1200 xx 1000 800 Revenue (in USDmillion) xx 600 xx 474.0 419.2 400 200 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  46. BY ENDUSER MARKETSEGMENTATION 55 7.4.1Hospitals 7.4.2 PharmaceuticalCompanies 7.4 SEGMENTATION – BY ENDUSER 7.4.3Others Report

  47. BY ENDUSER MARKETSEGMENTATION 56 Fig.1 Pharmacovigilance Market : Revenue Share (%), by End User, Global,2017 Fig.1 Pharmacovigilance Market : Revenue in USD billion, by End User, Global,2015-2023 xx xx xx Hospitals Pharmaceutical Companies Others Report

  48. HOSPITALS MARKETSEGMENTATION BY ENDUSER 57 Pharmacovigilance Market: Revenue in USD million, by End User, Hospitals, Global,2015-2023 1800 xx 1600 1400 1200 Revenue (in USDmillion) 1000 xx xx 800 677.7 598.8 600 400 200 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  49. PHARMACEUTICALCOMPANIES MARKETSEGMENTATION BY ENDUSER 58 Pharmacovigilance Market: Revenue in USD million, by End User, Pharmaceutical Companies, Global,2015-2023 7000 xx 6000 5000 Revenue (in USDmillion) 4000 xx xx 3000 xx xx 2000 1000 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

  50. OTHERS MARKETSEGMENTATION BY ENDUSER 59 Pharmacovigilance Market: Revenue in USD million, by End User, Others, Global,2015-2023 400 xx 350 300 Revenue (in USDmillion) 250 xx 200 xx xx xx 150 100 50 0 2015 2016 2017 2018 2023 Year Source: Prophecy Market Insights Report

More Related